Rifabutin for treating pulmonary tuberculosis

Author:

Davies Geraint R1,Cerri Stefania2,Richeldi Luca2

Affiliation:

1. University of Liverpool; School of Clinical Sciences; Royal Liverpool University Hospital Prescot Street Liverpool Merseyside UK L7 8XP

2. Policlinico di Modena, Universita di Modena e Reggio Emilia; Divisione di Pneumologia; Via del Pozzo 71 Modena Italy 41100

Publisher

Wiley

Subject

Pharmacology (medical)

Reference27 articles.

1. Rifabutin for the treatment of newly-diagnosed pulmonary tuberculosis: a multinational, randomized, comparative study versus Rifampicin. Rifabutin Study Group;Gonzalez-Montaner;Tubercle and Lung Disease,1994

2. A controlled study of rifabutin and an uncontrolled study of ofloxacin in the retreatment of patients with pulmonary tuberculosis resistant to isoniazid, streptomycin and rifampicin. Hong Kong Chest Service/British Medical Research Council;Hong Kong Chest Service/British Medical Research Council;Tubercle and Lung Disease,1992

3. Efficacy and safety of rifabutin in the treatment of patients with newly diagnosed pulmonary tuberculosis;McGregor;American Journal of Respiratory and Critical Care Medicine,1996

4. Preliminary results of rifabutine (ansamycine LM 427) treatment of patients with newly detected and chronic pulmonary tuberculosis and Mycobacterium infections;Rowinska-Zakrzewska;Pneumologia i Alergologia Polska,1992

5. A pilot study of antituberculosis combinations comparing rifabutin with rifampicin in the treatment of HIV-1 associated tuberculosis;Schwander;Tubercle and Lung Disease,1995

Cited by 57 articles. 订阅此论文施引文献 订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献

1. Recent efforts in the development of glycoconjugate vaccine and available treatment for tuberculosis;Bioorganic Chemistry;2024-09

2. Rifabutin central nervous system concentrations in a rabbit model of tuberculous meningitis;Antimicrobial Agents and Chemotherapy;2024-08-07

3. Chapitre 10: Le traitement de la tuberculose active chez les populations particulières;Canadian Journal of Respiratory, Critical Care, and Sleep Medicine;2023-11-02

4. Tuberculosis in Spain: An opinion paper;Revista Española de Quimioterapia;2023-11-02

5. Injectable controlled‐release systems for the prevention and treatment of infectious diseases;Journal of Biomedical Materials Research Part A;2023-09-23

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号  京ICP备18003416号-3